HUE027837T2 - Influenza vírus és olaj-a-vízben emulzió adjuváns alkalmazása CD4 T-sejtes és/vagy javított B-memória sejtes válasz indukálására - Google Patents

Influenza vírus és olaj-a-vízben emulzió adjuváns alkalmazása CD4 T-sejtes és/vagy javított B-memória sejtes válasz indukálására Download PDF

Info

Publication number
HUE027837T2
HUE027837T2 HUE06723805A HUE06723805A HUE027837T2 HU E027837 T2 HUE027837 T2 HU E027837T2 HU E06723805 A HUE06723805 A HU E06723805A HU E06723805 A HUE06723805 A HU E06723805A HU E027837 T2 HUE027837 T2 HU E027837T2
Authority
HU
Hungary
Prior art keywords
influenza
vaccine
oil
adjuvanted
mpl
Prior art date
Application number
HUE06723805A
Other languages
English (en)
Inventor
Emmanuel Jules Hanon
Jean Stephenne
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36441219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE027837(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0505998A external-priority patent/GB0505998D0/en
Priority claimed from GB0505989A external-priority patent/GB0505989D0/en
Priority claimed from GB0506000A external-priority patent/GB0506000D0/en
Priority claimed from GB0506004A external-priority patent/GB0506004D0/en
Priority claimed from GB0506001A external-priority patent/GB0506001D0/en
Priority claimed from GB0510589A external-priority patent/GB0510589D0/en
Priority claimed from GB0510596A external-priority patent/GB0510596D0/en
Priority claimed from GB0510593A external-priority patent/GB0510593D0/en
Priority claimed from GB0510591A external-priority patent/GB0510591D0/en
Priority claimed from GB0510598A external-priority patent/GB0510598D0/en
Priority claimed from GB0603789A external-priority patent/GB0603789D0/en
Priority claimed from GB0603788A external-priority patent/GB0603788D0/en
Priority claimed from GB0603790A external-priority patent/GB0603790D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of HUE027837T2 publication Critical patent/HUE027837T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (11)

  1. Szabadalmi igénypontok
    1. ΜΙϊμϊζο viras vagy anitgemkos MszlimOop Is ol^a-mizben emulzió adg-váns alkalmazása 65 éves vagy öregebb idős erafe^lc ärrBaenffir ellesí vakcinázssára szolgáló inmnmogén készítmény előállítására, ahol az. olaj-o-vizben etnoizk:· aKnaitoilzáibatO olajat, allá-lokofetok és; emuígeálószert tartahnaz.
  2. 2, Ax L. ígénytxmt sgermi slkiilmgKás, ahoi a készítmény lavitot? CÍM T-sejtes: imtmtnválaszl: indokéi a y i rmt vagy ami gén ikm készítménye ellen az idés alanyban, 3> Az 1, vagy 2. igßtypmt ssssedtiíí: sijfeitaesiss*, siöí. ** .älsj^Äte«. ää olyan oístieseppaket tartalmaz, amelyeknek legalább 70% imonzhásímn kisebb mini 1 gm az mmérdjs.
  3. 4, Az 1-3. igénypontok Mtmelylke szerinti slkakostzas, ahöl az oiaj-azyfciw emuláló olyan olajcseppeket tartalmaz. amelyeknek legalább 70% intenzitásban kisebb mint 500 ran a?, átmérője.
  4. 5, Az 1-4. igénypontok bármelyike szerinti aikaimaXfe, ahol az. olaj-a-vlzben emulzió olyan olaj cseppeket tartalmaz. amelyeknek legalább s{)% intenzitásban kisebb mini 300 nm az átmétöje. 6. A.< 1-8. igénypocsíok básmelyike szerinti aíkahnazás. ahol az olaj-a-vlzben emulzió olyan oktjeseppekd ttótthttaz, ataelpkaek legalább 90% Mösbííihsbap a 120-200 pm tartományba esik az átmérőié.
  5. 7. Az I -6. igénypontok bármelyike szerinti alkalmazás, ahol as: aiia-tokoferol I ,.ö% * 20% mentsylségixm van jelen az- immunogén készhmé®y i«yos^rtbgmára azámttm 7, A 7. igénypont szerinti alkat immas, ahol az attá-iökoíeroi 1,0¾¾ - 5,0¾¾ mennyiségben van jelen az Immunogen készítmény telles térfogatára számított. fi Μ1 -ü, igdnypotök: hámmy tke szerinti álkslnrazás, s&amp;eî aysetsbolMlhaté olaj; szkvalén. IÉ, Az t-O, Igénypomok bármelyike szëAoti kéazhméay, ahol a omtábohMlhaté olaj Ö,S% - 20% mennyiségben yan jelén m immunogemkus készllmény teíjes iéríoptára vratmkoztmva. ΙΙ, ,Α ΙΘ. igénypont Azeristi készítmény» alsóba mélából izáihstö ólai 1,0%-100¾ mennyiséiben van Jelen az tmmttttogemkas készítmény:télíes térfegatÉ«; yoamkozimva. I&amp; A :i l, Igéttypösit íszerlnt; készítmény, ahol; a mmaboiszálható oké 2,0% - íp% mennyisége«® van Jelen: az Immunogentbus készítmény : tell es térlogntára: semtkoztatva,
  6. 13, Az 142:. igénypontok bármelyike: szerinti alkalmazás, ahol az olapa-vizbssv emtilziö továbbá sztárok is tartalmaz. 14, A. 13. igénypont szerinti alkalmazás,..absba:további szierol koleszterin, IS: A:0-14, : liényporítök bánnelylke szertett alkalmazás, ahol a szkva]én:ailsAokofbro.l arány kisebb vagy egyenlő mini: 1. ii< Az .1» 15.. Igénypontok:bármelyike szérhilláikalmazás, sítől az emulgsálészor Ityeon-kö; 17:A 161 igénypont szérinit készitménys ahol az emtsipálószer ô,0! - Sß fönmg% mennyiségben van jelen sz intmsnogeosktfá készíttnéityben. 18« A I?.Igénypont:szerimi ikészhutény, ahol az emuigeáiószer 0,1 - 2,04ömef% mennyiségben m\ jelen az Immunogenikus Mszitfnénybe!):. 1.9, Az 14:8. Igénypontok bármelyike szerinti: alkalmazás, ahol az ölapa-vizben stmdzió a kővetkező összetételű: 248% szkvalén, 246% aiia-tokoterolsés:0,3-3% Tween-80.
  7. 20, Αχ Μ9, igénypontok bàttnétyiké szénntt ájkáfazás, ahöí 8¾ rmmttnögésr késziíplégy továbbá TI.R~4 ligandumot is iarndmaz. 21, A 20. igénypert? s.xeriMi ákaiíMzák: gfeôl 0 TUM l%aa4um. a kbvÂzôk által aikotottkstârôi vaa kiváltóivá: Íipid-A nam-ioxikos tótf. JSËÉIuÎ 3#rMfÍ4 Íipid-A szintetikus száriPakéka; RíDP; ës RSV F protein. 22, Λ 21. igénypont szeriül? alkalmazás, ahol a llpid-A származék 3D-MPL. 23, A 22 igénypont s/eAnti alkaísnaxás, altot a 3D-MPL 1Ö » 50 gg (w/v) tnentívíségben van jelen k0sxiín)0ny-;ióxis<íi',ként, 24, A 25, igénypont szerinti alkalmazás, ahol a 3D-MPL körülbelül 25 p.g (w/v) mennyiségbe?? van jekn késÂtéiiy-dox iso??ké; ??;,
  8. 23, Ak K?4 igénypontok bármelyike szerinti alkalmazás., ahol a? immugjbfj&amp;g. jk^iüBÖBV beadása továbbá jpltött CDI 1 -sejtes; immtraváia&amp;zt és javítón B-memóró sejk-;; választ is. índítkál· 20, influenza virus vagy autigemku*. készbtnénye alkalmazása influenza yirlipál vagy anilgenikus készítményével és rnetabulizáíható olajat, alfa-tokoieroli es emulgeálószeri ?nsr;?jnu?z,é olaj~a~vizbea emulzió adjaváMS;ti korábban már vakeifiáZött 65 éve» vágy öregebb Idős etnberek ájtsViiléiháiÉSiárá szolgáló kmMgögáö készilrnény gyártására, afeöí sä ájtavakemázásrá szolgáló lMs:öaogéft készfenlsiy ijtóíöt? mitoenza ySmst vagy baaiíob vírus a?ttígeuikus készítményét íartaímáSza, amely í) közös CD4 T-sejt ép itófrök, in) közös B-sáit epítópok iegalább egyikében megegyezik az első vakeínásra íúkalutszolí íniloesza virtsssol or asitlpníküs készlbpényéyel, 27, A 26. igénypont szerinti alkalmazás, ahol az áimvakcinázásra aíkaintazob készítmény aájuvánst tarmbnnz:. 23, A 27. igénypont szerinti alktdntaxás. ahol az adjuváns a kővetkezők által alkotott listáról van kiválasztva: olaj a-víaben cmiiízíó adjuvánm anso>in;u?t? adjuváns, Tf.R-4 iigandum, szaponin, 25, A 26-28. igénypontok bármelyike szerinti alkalmazás, ahol az. olaj-a-vizben emulzió adjuváns az 1. és 3-19. igénypontok bármelyikében definiál? és a Tl.R-4 iígartdam a 21-24. igénypontok bármelyikében defidiált·: 36. A 26-29. igéîiyponiok bármelyike szerinti alkalmazás, ahol az újravakctnázás utáni immunválasz kővetkezők bármelyike vagy -azok közül kettő vagy ntindegyífe: javítóit C.P4- válasz inllnenza vírus vagy tpííigéSttte készáménye eben, vág) taviiott iumxíráHk váltó vagy javított E-sejt memóriáé válasz.
  9. 31. Az 1-30. igénypofitok bármelyike szermti alkalmazás, ahol a,·: influenza virus vagy aniigenikns készítménye monovalens. bivitkms vagy trivakms
  10. 32. AZ 1--31, Igéiryponíok bármelyike szerint? alkáimszás, ahol m iílBbénza vírus Vágy íi:ítti|apikus készIbPénye háton! ikblönbOzö Influenza törzsből származik, 33. A 32. igénypont szerinti stlkalmtótg aboi legalább egy törzs pand&amp;más játvártüpl: ífcapcsötes ipötettétilíSifi. pandám tás járvánnyá! kápóápiiátóá< 34. A 33. igénypont szermtí áikalínazás, ahol a pndéspiás törzs a következők áitakalkotött ilsíátf 1 van kiválasztva: H SM i, H9N2, H.7N7, H2N2 és MINI. 35.  26-34. ia.áísvponKsk svannia alksbu^ss, ahol ax sisö ssAvankaas alysn anlaanxs törzset tarblíaazé ihasfto8::.«*0ttms .k^fcnénrtyel van yég«««©, :3TOβ¾^:po^8ßtÄta:^!k^>^. pôàëîs%::jànfàttÿ'' :akozlÄs 6s:aÄ :öiravakvinäxS«^rS?igö |3;m66mläa: ^i-Kxaal van vágasm 362ÂK 1-25, igénypoatak MriWi8|^i5!fc.?sa5®Âî íaikbtnaxás, sins! 8¾. kösnsnogéí: íslkaspuy. dógiaö HA aatigá-a tartalma:.··:.. $%,&amp;?< 1-36. Ig&amp;íVpcííídA ASnnaÎÿBve aratinl! alkalmai?», ahoi m inSae»?»· aotigês vagy anràpaîtes késziftnényn kpas-eredetü vagy saöveíienyéaxet-aredeki.
  11. 38. Ás 1-37. ahni aK :kí!teíf^a viras a köveíkekők |M alkotok listáról van kiválásaivá; hasikat inlfenva viras. Mfss nsfluanm Yfeas, alegység mäagnsa viras, biaéaza virasAnaa és írnek aniigerukus késAariénye. 38.A 3S:. Igsayponi szst'íoií .g!k#m8sá&amp; -«Mi Í8s8^:l8Éu«g8 vims antigea vágy anísgenikns késAkoényv.
HUE06723805A 2005-03-23 2006-03-21 Influenza vírus és olaj-a-vízben emulzió adjuváns alkalmazása CD4 T-sejtes és/vagy javított B-memória sejtes válasz indukálására HUE027837T2 (hu)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB0505989A GB0505989D0 (en) 2005-03-23 2005-03-23 Compositions
GB0506000A GB0506000D0 (en) 2005-03-23 2005-03-23 Novel use
GB0506004A GB0506004D0 (en) 2005-03-23 2005-03-23 Compositions
GB0506001A GB0506001D0 (en) 2005-03-23 2005-03-23 Novel use
GB0505998A GB0505998D0 (en) 2005-03-23 2005-03-23 Novel compositions
GB0510596A GB0510596D0 (en) 2005-05-24 2005-05-24 Composition
GB0510589A GB0510589D0 (en) 2005-05-24 2005-05-24 Novel use
GB0510593A GB0510593D0 (en) 2005-05-24 2005-05-24 Novel compositions
GB0510591A GB0510591D0 (en) 2005-05-24 2005-05-24 Novel use
GB0510598A GB0510598D0 (en) 2005-05-24 2005-05-24 Composition
GB0603789A GB0603789D0 (en) 2006-02-24 2006-02-24 Novel use
GB0603788A GB0603788D0 (en) 2006-02-24 2006-02-24 Novel composition
GB0603790A GB0603790D0 (en) 2006-02-24 2006-02-24 Composition

Publications (1)

Publication Number Publication Date
HUE027837T2 true HUE027837T2 (hu) 2016-11-28

Family

ID=36441219

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE06723805A HUE027837T2 (hu) 2005-03-23 2006-03-21 Influenza vírus és olaj-a-vízben emulzió adjuváns alkalmazása CD4 T-sejtes és/vagy javított B-memória sejtes válasz indukálására

Country Status (24)

Country Link
US (5) US20080171063A1 (hu)
EP (4) EP1861120B1 (hu)
JP (4) JP5869744B2 (hu)
KR (5) KR20160064249A (hu)
AR (3) AR053833A1 (hu)
AU (3) AU2006226458B2 (hu)
CA (3) CA2601022C (hu)
CY (1) CY1117874T1 (hu)
DK (1) DK1861120T3 (hu)
EA (3) EA200701787A1 (hu)
ES (1) ES2585810T3 (hu)
HR (1) HRP20160816T1 (hu)
HU (1) HUE027837T2 (hu)
IL (3) IL185897A (hu)
MA (3) MA30298B1 (hu)
MX (3) MX2007011756A (hu)
NO (3) NO20074638L (hu)
NZ (2) NZ561822A (hu)
PE (3) PE20061300A1 (hu)
PL (1) PL1861120T3 (hu)
PT (1) PT1861120T (hu)
SI (1) SI1861120T1 (hu)
TW (3) TW200722101A (hu)
WO (3) WO2006100109A1 (hu)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1154790B1 (en) * 1999-02-26 2004-10-20 Chiron S.r.l. Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20100221284A1 (en) * 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
CA2601022C (en) * 2005-03-23 2023-03-07 Glaxosmithkline Biologicals S.A. Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP2377551A3 (en) * 2005-11-04 2013-04-24 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
AU2006310340B2 (en) * 2005-11-04 2011-02-10 Novartis Ag Changing TH1/TH2 balance in split influenza vaccines with adjuvants
PT2368572T (pt) * 2005-11-04 2020-06-16 Seqirus Uk Ltd Vacinas com adjuvante dotadas de antigénios não-virião preparados a partir de vírus da gripe cultivado em cultura celular
NZ568210A (en) * 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
FR2896162B1 (fr) * 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
EP1991264B1 (en) 2006-03-07 2015-01-07 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
JP2009534303A (ja) * 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
EA017441B1 (ru) * 2006-06-15 2012-12-28 Новартис Аг Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы
CA2583555C (en) * 2006-07-17 2020-01-07 Glaxosmithkline Biologicals S.A. Influenza vaccine
WO2008009309A1 (en) 2006-07-17 2008-01-24 Glaxosmithkline Biologicals S.A. Influenza vaccine
CN105727276A (zh) * 2006-07-17 2016-07-06 葛兰素史密丝克莱恩生物有限公司 流感疫苗
BRPI0717219B8 (pt) * 2006-10-12 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, e, uso de uma composição imunogênica
EP2433648A3 (en) * 2006-10-12 2012-04-04 GlaxoSmithKline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
EP1923070A1 (en) * 2006-11-15 2008-05-21 Intervet International BV Vaccine for vaccinating feline against influenza virus
EA200900784A1 (ru) * 2006-12-06 2009-12-30 Новартис Аг Вакцины, включающие антиген из четырех штаммов вируса гриппа
EP1938835A1 (en) * 2006-12-29 2008-07-02 Pevion Biotech AG Non-specific immunostimulating agents
JP2010519316A (ja) * 2007-02-23 2010-06-03 ベイラー リサーチ インスティテュート デクチン−１を介したヒト抗原提示細胞の活性化の治療への応用
AR066405A1 (es) * 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
CA2700937C (en) * 2007-10-12 2017-05-09 Csl Limited Method of eliciting an immune response against pandemic influenza virus
PL2200642T3 (pl) * 2007-10-19 2012-09-28 Novartis Ag Preparaty szczepionek meningokokowych
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CA2707247A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Influenza composition
US8426163B2 (en) * 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
EP2889042A3 (en) * 2008-03-18 2015-10-14 Novartis AG Improvements in preparation of influenza virus vaccine antigens
SG190562A1 (en) 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
GB0905570D0 (en) * 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
EP2310045A1 (en) 2008-06-25 2011-04-20 Novartis AG Rapid responses to delayed booster immunisations
EP2396032B1 (en) 2009-02-10 2016-09-28 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
CN102438651A (zh) 2009-02-10 2012-05-02 诺华有限公司 用于大流行相关毒株的流感疫苗方案
AU2015203072B2 (en) * 2009-02-10 2017-05-25 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
US8287880B2 (en) * 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
WO2010148496A1 (en) * 2009-06-22 2010-12-29 National Health Research Institutes Lipidated tumor- associated antigens and immunotherapeutic compositions
EP2289575B1 (de) * 2009-08-06 2017-07-05 Biotronik VI Patent AG Medizinisches Implantat enthaltend eine antioxidative Substanz
CN107582526A (zh) * 2009-08-12 2018-01-16 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
EP2308506A1 (en) 2009-10-02 2011-04-13 Mucosis B.V. Adjuvanted intranasal vaccine formulations
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
AU2013202690B2 (en) * 2009-12-03 2016-02-11 Novartis Ag Hydrophilic filtration during manufacture of vaccine adjuvants
EP2601933B1 (en) * 2009-12-03 2015-10-07 Novartis AG Hydrophilic filtration during manufacture of vaccine adjuvants
RS52565B (en) * 2009-12-03 2013-04-30 Novartis Ag METHOD OF INTERACTION AND REVERSE PRESSURE FOR MICROFLUIDIZATION
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056871A1 (de) * 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EP2638895B1 (en) 2009-12-03 2024-03-20 Seqirus UK Limited Circulation of components during homogenization of emulsions
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
BR112012018343A2 (pt) * 2009-12-22 2017-06-27 Sanofi Pasteur Ltd "composições imunogênicas"
JP2013516469A (ja) * 2010-01-06 2013-05-13 ヴァクシネイト コーポレイション 高齢者に保護免疫を提供するための方法及び組成物
WO2011088451A1 (en) * 2010-01-15 2011-07-21 Novavax, Inc. Uses of influenza virus-like particles (vlps) for characterization of neuraminidase and hemagglutinin activity
RU2527688C2 (ru) * 2010-02-27 2014-09-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностого антигена н1n1 и лекарственное средство для лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена н1n1
GB201009673D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009671D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009676D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
CN104884086A (zh) * 2012-12-28 2015-09-02 日本国立感染症研究所 经鼻流感疫苗组合物
EP2801372A3 (en) * 2013-05-10 2015-02-18 Novartis AG Avoiding narcolepsy risk in influenza vaccines
CN104436157A (zh) * 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
US10080792B2 (en) * 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
JP2017528511A (ja) * 2014-09-26 2017-09-28 セキラス ユーケー リミテッド 免疫低下された被験体のワクチン接種
WO2019108928A1 (en) * 2017-11-30 2019-06-06 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
CA3127639A1 (en) * 2019-01-30 2020-08-06 Glaxosmithkline Biologicals Sa Oil/surfactant mixtures for self-emulsification
US20230054162A1 (en) * 2019-12-20 2023-02-23 Fresenius Kabi Austria Gmbh Methods for producing oil-in-water emulsions
RU2741003C1 (ru) * 2020-03-27 2021-01-22 Евгений Дмитриевич Некрасов Способ производства четырехвалентной субъединичной вакцины против гриппа без адъювантов
WO2022002783A1 (en) 2020-06-29 2022-01-06 Glaxosmithkline Biologicals Sa Adjuvants
BR112023002706A2 (pt) 2020-08-24 2023-03-14 Sanofi Pasteur Inc Vacinas contra infecções por sars-cov-2
AU2021330836A1 (en) 2020-08-24 2023-05-04 Glaxosmithkline Biologicals Sa Covid-19 vaccines with tocopherol-containing squalene emulsion adjuvants
KR102270165B1 (ko) 2020-10-22 2021-06-28 한국화학연구원 세정제 조성물
EP4313137A1 (en) 2021-03-26 2024-02-07 GlaxoSmithKline Biologicals SA Immunogenic compositions
BR112023027401A2 (pt) 2021-06-28 2024-03-12 Glaxosmithkline Biologicals Sa Antígenos do vírus influenza
RU2766292C1 (ru) * 2021-08-05 2022-03-14 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства (ФГУП СПбНИИВС ФМБА России) Состав вакцины против covid-19
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023061993A1 (en) 2021-10-13 2023-04-20 Glaxosmithkline Biologicals Sa Polypeptides

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095974A (en) * 1961-10-27 1963-07-02 Anthony R Perini Collapsible book rack
US4047869A (en) * 1973-02-23 1977-09-13 Mulvany Jr R F Apparatus for forming plastic articles
FR2333610A1 (fr) * 1975-12-03 1977-07-01 Zhdanovsky Z Tyazhelogo Mash Bande-electrode a ame en poudre pour rechargement a l'aide d'un alliage resistant a l'usure
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
DD155875A1 (de) 1980-12-31 1982-07-14 Willy Nordheim Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
DD211444A3 (de) 1982-08-19 1984-07-11 Saechsisches Serumwerk Verfahren zur herstellung von influenza-impfstoffen
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DD300833A7 (de) 1985-10-28 1992-08-13 Saechsische Landesgewerbefoerd Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
WO1988009797A1 (en) 1987-06-05 1988-12-15 The United States Of America, As Represented By Th Autocrine motility factors in cancer diagnosis and management
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
DE3734306A1 (de) 1987-10-10 1989-04-27 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer fliessfaehige medien
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8821049D0 (en) 1988-09-08 1988-10-05 Health Lab Service Board Method & composition for treatment & prevention of viral infections
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
DE69015222T2 (de) * 1989-02-04 1995-05-04 Akzo Nv Tocole als Impfstoffadjuvans.
US5092235A (en) 1989-05-24 1992-03-03 Tektronix, Inc. Pressure fixing and developing apparatus
WO1990014837A1 (en) * 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
DE4005528C2 (de) 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
WO1991013261A1 (en) 1990-03-02 1991-09-05 Experimentalny Nauchno-Issledovatelsky Institut Metallorezhuschikh Stankov Digital servo drive
US5149531A (en) * 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
CN1124013A (zh) * 1993-02-19 1996-06-05 史密丝克莱恩比彻姆公司 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物
WO1994019013A1 (en) 1993-02-19 1994-09-01 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
ATE204762T1 (de) 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
RU2154068C2 (ru) 1993-11-17 2000-08-10 Лаборатуар Ом С.А. Глюкозаминовые дисахариды, способ их получения, фармацевтическая композиция
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP0746338B1 (en) 1994-02-24 2004-10-27 Micro-Pak, Inc. Vaccines containing paucilamellar lipid vesicles as immunological adjuvants
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5916879A (en) 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
EP1009382B1 (en) * 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
ATE339223T1 (de) * 1998-03-09 2006-10-15 Glaxosmithkline Biolog Sa Kombinierte impfstoffzusammensetzungen
US6838269B1 (en) 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
CA2330610A1 (en) 1998-05-07 1999-11-11 Corixa Corporation Adjuvant composition and methods for its use
HUP0102332A3 (en) 1998-06-08 2002-11-28 Sca Emballage France Fast flattening packaging
WO2000000462A1 (fr) 1998-06-30 2000-01-06 Om Pharma Nouveaux pseudodipeptides acyles, leur mode de preparation et les compositions pharmaceutiques en renfermant
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
CA2689696C (en) 1999-02-26 2013-08-06 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
FR2796291B1 (fr) 1999-07-16 2001-09-21 Cross Site Technologies Seringue sans aiguille munie d'un systeme de declenchement piezo-electrique
FR2796290B1 (fr) 1999-07-16 2001-09-14 Cross Site Technologies Seringue sans aiguille fonctionnant avec un generateur d'onde de choc a travers une paroi
FR2796289B1 (fr) 1999-07-16 2001-08-10 Cross Site Technologies Seringue sans aiguille avec injecteur a elements superposes
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
FR2800619B1 (fr) 1999-11-05 2002-02-08 Cross Site Technologies Seringue sans aiguille avec un moyen de poussee temporairement retenu
FR2802103B1 (fr) 1999-12-08 2003-10-03 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec entrainement du principe actif par effet tube a choc
FR2802102B1 (fr) 1999-12-08 2002-07-12 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un tube d'ejection a section constante
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
FR2802820B1 (fr) 1999-12-27 2002-10-18 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant par effet tube a choc, avec maintien prealable du principe actif sur le cote
US20030158134A1 (en) 2000-01-31 2003-08-21 Gerald Voss Vaccine for the prophylactic or therapeutic immunization against hiv
FR2804329B1 (fr) 2000-02-02 2002-12-13 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un opercule contenant le principe actif
FR2804869B1 (fr) 2000-02-11 2002-05-17 Poudres & Explosifs Ste Nale Seringue sans aiguille pour l'injection d'un liquide contenu dans une ampoule pre-remplie
FR2805749B1 (fr) 2000-03-01 2002-05-17 Poudres & Explosifs Ste Nale Seringue sans aiguille a deux niveaux de vitesse d'injection
FR2807946B1 (fr) 2000-04-19 2002-06-07 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec un chargement pyrotechnique bicomposition
FR2809626B1 (fr) 2000-05-30 2003-03-07 Poudres & Explosifs Ste Nale Seringue sans aiguille avec membrane d'isolation d'un ejecteur multiconduit
FR2810554B1 (fr) 2000-06-22 2003-05-16 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un reservoir modulable
FR2812202B1 (fr) 2000-07-28 2002-09-13 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant par mise en compression du reservoir contenant le principe actif liquide
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
FR2815544B1 (fr) 2000-10-23 2003-02-14 Poudres & Explosifs Ste Nale Seringue sans aiguille securisee a architecture compacte
EP1201250A1 (en) 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
JP5208347B2 (ja) 2001-02-23 2013-06-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規なワクチン
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
WO2003084467A2 (en) * 2002-04-01 2003-10-16 Euro-Celtique S.A. Epitope constructs comprising antigen presenting cell targeting mechanisms
JP4675317B2 (ja) 2003-01-30 2011-04-20 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アジュバント化インフルエンザワクチン
CA2559371C (en) * 2004-03-09 2014-07-08 Chiron Corporation Influenza virus vaccines
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
CA2601022C (en) * 2005-03-23 2023-03-07 Glaxosmithkline Biologicals S.A. Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
WO2007130330A2 (en) 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
WO2008009309A1 (en) * 2006-07-17 2008-01-24 Glaxosmithkline Biologicals S.A. Influenza vaccine
CN105727276A (zh) * 2006-07-17 2016-07-06 葛兰素史密丝克莱恩生物有限公司 流感疫苗
BRPI0717219B8 (pt) 2006-10-12 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, e, uso de uma composição imunogênica
AR066405A1 (es) * 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
CA2707247A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Influenza composition

Also Published As

Publication number Publication date
AR054020A1 (es) 2007-05-30
KR20070116651A (ko) 2007-12-10
CA2603180A1 (en) 2006-09-28
KR101916787B1 (ko) 2019-01-24
NO20074638L (no) 2007-12-19
TW200700079A (en) 2007-01-01
JP5770414B2 (ja) 2015-08-26
PE20061387A1 (es) 2007-01-19
EP1861120A1 (en) 2007-12-05
MX2007011748A (es) 2008-03-11
EP1861120B1 (en) 2016-05-25
EP1863529A1 (en) 2007-12-12
EA011419B1 (ru) 2009-02-27
IL185897A (en) 2015-11-30
AU2006226458B2 (en) 2012-08-30
HRP20160816T1 (hr) 2016-08-12
JP2014129359A (ja) 2014-07-10
EA011393B1 (ru) 2009-02-27
NZ561823A (en) 2010-04-30
IL185901A0 (en) 2008-01-06
EA200701787A1 (ru) 2008-08-29
JP2008534467A (ja) 2008-08-28
ES2585810T3 (es) 2016-10-10
MA29715B1 (fr) 2008-09-01
US20140363474A1 (en) 2014-12-11
CA2603180C (en) 2015-10-13
MA30298B1 (fr) 2009-04-01
CA2601022C (en) 2023-03-07
CY1117874T1 (el) 2017-05-17
AU2006226459A1 (en) 2006-09-28
NZ561822A (en) 2010-04-30
US20110287054A1 (en) 2011-11-24
EP1861122A1 (en) 2007-12-05
WO2006100109A1 (en) 2006-09-28
MA29342B1 (fr) 2008-03-03
CA2601022A1 (en) 2006-09-28
AU2006226543A1 (en) 2006-09-28
IL185897A0 (en) 2008-01-06
MX2007011756A (es) 2008-03-11
AU2006226458A1 (en) 2006-09-28
CA2602456A1 (en) 2006-09-28
DK1861120T3 (en) 2016-07-25
IL185906A0 (en) 2008-01-06
KR20140004815A (ko) 2014-01-13
US20080181911A1 (en) 2008-07-31
EA200701785A1 (ru) 2008-04-28
KR20070116652A (ko) 2007-12-10
AU2006226543B2 (en) 2011-10-06
EP2397153A1 (en) 2011-12-21
AR053833A1 (es) 2007-05-23
US20080171063A1 (en) 2008-07-17
JP5869744B2 (ja) 2016-02-24
PE20061300A1 (es) 2006-12-23
WO2006100111A1 (en) 2006-09-28
NO20074930L (no) 2007-12-07
WO2006100110A1 (en) 2006-09-28
TW200700078A (en) 2007-01-01
PE20061428A1 (es) 2007-01-16
PL1861120T3 (pl) 2016-11-30
US20090081253A1 (en) 2009-03-26
SI1861120T1 (sl) 2016-09-30
AR052625A1 (es) 2007-03-21
KR20070116650A (ko) 2007-12-10
NO20074635L (no) 2007-12-19
EA200701786A1 (ru) 2008-04-28
JP2008534466A (ja) 2008-08-28
JP2008534465A (ja) 2008-08-28
KR20160064249A (ko) 2016-06-07
MX2007011775A (es) 2008-03-11
US9730999B2 (en) 2017-08-15
PT1861120T (pt) 2016-08-18
TW200722101A (en) 2007-06-16

Similar Documents

Publication Publication Date Title
US9730999B2 (en) Adjuvanted influenza virus compositions
KR101696727B1 (ko) 인플루엔자 백신
KR101188382B1 (ko) 수중유 에멀젼 인플루엔자 백신
EP2422810B1 (en) Influenza vaccine
US20090028903A1 (en) Novel use
CA2583555C (en) Influenza vaccine
BRPI0609516A2 (pt) uso de um vìrus de influenza ou preparação antigênica do mesmo e um adjuvante de emulsão de óleo-em-água, e, método para projetar uma vacina para doenças conhecidas por serem curadas ou tratadas por meio de uma ativação de células tcd4+